Navigate Fool.com
Will ALPMY beat
the market?


13.83 0.19 (1.36%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.87
Previous Close $13.64
Daily Range $13.77 - $13.87
52-Week Range $9.74 - $14.97
Market Cap $31.2B
P/E Ratio 0.00
Dividend (Yield) $0.00 (1.6%)
Volume 20,131
Average Daily Volume 43,637
Current FY EPS $0.45

How do you think ALPMY
will perform against the market?

Top ALPMY Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

What You Need to Know About Medivation Inc.'s Results

Medivation (MDVN) and Astellas (ALPMY) saw U.S. sales growth slow this quarter, but growth overseas took off. Here's what could be in store for these stocks through the rest of the year.

Why Medivation Inc. Shares Roared Higher

Medivation shares surge after it reports its first-quarter earnings results after the closing bell last night. Can shares head even higher?

Medivation's Q1 Loss Shrinks by 50% as Xtandi Revenue Soars

Medivation and Astellas Pharma's Xtandi sales take off both inside and outside the U.S., helping Medivation halve its quarterly loss from the year-ago quarter.

Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca

Bayer, Merck, Medivation, and AstraZeneca could all loom large in health care headlines this Tuesday morning. Here’s why.

Is There Value In Cytokinetics Following Its 60% Drop?

Cytokinetics (CYTK) mid stage trial for its promising ALS drug failed, shifting attention to collaborations with Amgen (AMGN) and Astellas (ALPMY).

3 Drugs Johnson & Johnson’s Investors Better Know About

Johnson & Johnson's (JNJ) sales are being driven by a handful of fast-growing drugs. Here are three investors should be watching because of competitive threats from AstraZeneca (AZN), Pfizer (PFE), and Medivation (MDVN).

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.

Why I Bought Exelixis

The author shares his opinion why the recent drop in Exelixis is an incredible buying opportunity.

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.

Was Medivation's Quarter a Disaster?

Medivation (MDVN) shares sank more than 10% on news of slowing sales growth for its prostate cancer drug Xtandi; however, an FDA decision and potential milestones may support the company into year end.

See More ALPMY News...





Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks